Weigh nivolumab–ipilimumab benefits versus immune toxicities in HCC, factoring patient comorbidities, access, preferences, and the urgent need for predictive biomarkers.
Mehmet Akçe, MD, University of Alabama at Birmingham, Birmingham, AL
Advertisement
Articles by Mehmet Akçe, MD, University of Alabama at Birmingham, Birmingham, AL
In HCC, CheckMate-9DW shows nivolumab–ipilimumab preserves quality of life; early immune toxicities are common but manageable without losing
Frontline HCC experts weigh atezolizumab-bevacizumab, STRIDE, and nivolumab-ipilimumab, using ALBI and social support to guide safer choices.
Frontline HCC therapy choices weigh immunotherapy regimens, ALBI liver function and support needs, highlighting gaps for Child-Pugh B/C patients.
In HCC, IMbrave050 tempers adjuvant atezo-bev hopes as final data weakens RFS gains, highlighting unmet need and new trials.
For HCC with portal vein invasion, experts urge baseline EGD for varices to guide anti-VEGF use and reduce bleeding risk.
Experts break down first-line unresectable HCC choices—STRIDE, atezo/bev, nivo/ipi—balancing cirrhosis, comorbidities, and immunotherapy risks.
Dual-checkpoint HCC toxicities peak weeks 3–15; experts share monitoring and steroid-first hepatitis management, plus cautious rechallenge strategies and emerging IL‑6 approaches.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
2
Imaging Cadence, Radiation Timing, and Osimertinib Dosing Frame CNS Management Decisions in EGFR-Mutated NSCLC
3
Improved Outcomes for High-Risk CLL Remain Key Focus for Continued Development of Fixed-Duration Regimens
4
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
5